Business · 27/01/2026Updated: 10/16/2026 · 1 min read
FDA Regulatory Review Period Determination for SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM
Summary
The FDA has determined the regulatory review period for the SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM, a medical device, due to patent extension applications submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →